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Abstract: 
CELLULAR RESPONSE TO PROSTHETIC WEAR DEBRIS DIFFERS IN 
RHEUMATOID VERSUS NON-RHEUMATOID ARTHRTIS. Anant Vasudevan, 
Edward F. DiCarlo, Timothy Wright, Dan Chen, Mark. P Figgie, Steven R. Goldring, 
Lisa A. Mandl. Department of Rheumatology, Hospital for Special Surgery, Weill 
Cornell Medical College, New York, NY. (Sponsored by Carrie Swigart, Department of 
Orthopaedics and Rehabilitation, Yale University School of Medicine). 
 
 In the setting of inflammatory arthritis, the histopathologic reaction to foreign 
body wear debris generated from a failing arthroplasty has not been definitively 
characterized. This study examined whether patients with rheumatoid arthritis (RA) 
demonstrate different patterns of prosthetic wear or cellular responses to implant wear 
debris compared to patients without inflammatory joint disease. Thirty-eight patients who 
had a primary revision of a total elbow arthroplasty (TEA) for aseptic loosening between 
1996 and 2008 were identified. Twenty-five had RA and 13 had no inflammatory 
arthritis. Clinical data, gross wear patterns of the removed prostheses, and 
histopathological analyses of peri-implant tissue were compared between RA and non-
RA patients. Evaluation of the retrieved prostheses showed that conformational change of 
the humeral polyethylene bushing was associated with the generation of polyethylene and 
metal particles. The amount and type of wear debris in peri-prosthetic tissues was similar 
in RA and non-RA patients. RA patients not on anti-tumor necrosis factor (TNF) therapy 
exhibited a histologic pattern of interstitial and sheet-like lymphocytic infiltrates 
associated with a high plasma cell composition, which was different from the 
predominantly perivascular infiltrates with few plasma cells seen in non-RA patients (p-
value = 0.04). RA patients on anti-TNF therapy showed a mixed perivascular and 
interstitial pattern of infiltrates with variable plasma cell composition. Based on this data, 
we propose that RA patients exhibit a distinct cellular response to implant wear debris 
compared with non-RA patients. This reaction was unrelated to differences in the type or 
amount of wear debris and was mitigated by anti-TNF therapy. These results suggest an 
intrinsic alteration in immunoregulation in RA and have implications for potential 
immunologic treatment of osteolysis in these patients. 
 
 
 
 
     3
Acknowledgments: 
I would like to thank Dr. Mandl, Dr. Goldring, Dr. DiCarlo, and Dr. Wright for their 
support, mentorship, guidance, and encouragement throughout this inspiring research 
experience. I really appreciate the opportunity to have worked at HSS and been a part of 
this translational project with such a phenomenal group of physicians and scholars. 
 
In addition, I would like to acknowledge the Yale University School of Medicine Office 
of Student Research for its support of my thesis project. 
 
Thank you to my Yale faculty advisor, Dr. Carrie Swigart, who provided feedback and 
guidance from the time of my initial research proposal to the writing of this thesis. 
 
Finally, thank you to all of my friends and family for their love and support. 
 
 
Funding: 
Financial support for this project was provided to Anant Vasudevan by a Yale 
University School of Medicine Medical Student Research Fellowship, Summer 
Student Fellowship from the New York Chapter of the Arthritis Foundation, and ACR 
REF/Abbott Medical and Graduate Student Achievement Award. Dr. Steven Goldring 
was supported by a grant from the American College of Rheumatology Research and 
Education Fund, Within Our Reach. Dr. Mandl was supported by a K23AR050607 
grant from NIH/NIAMS and CERT Grant from AHRQ U18 HS016075. 
 
Financial Disclosures/Conflict of Interest: 
Dr. Steven Goldring has the following commercial financial disclosures: research grants 
from Boehringer Ingelheim and consulting for Merck Serono, Novartis, Pfizer 
Pharmaceuticals, Bone Therapeutics, and Roche. Dr. Timothy Wright has the following 
commercial financial disclosures: research grants from Stryker and Synthes Spine, stock 
ownership in Exactech, royalties from Mathys ABG, and an editorial honorarium from 
the Orthopaedic Research Society. Dr. Figgie has one commercial financial disclosure: 
research grants from Ethicon. 
 
 
A manuscript based on the results of this study has been accepted in Arthritis and 
Rheumatism. The article is currently published online per the following citation: 
 
Vasudevan A, DiCarlo E, Wright T, Chen D, Figgie M, Goldring S, Mandl  
 L. “Cellular Response to Prosthetic Wear Debris Differs in Rheumatoid  
 Versus Non-Rheumatoid Arthritis Patients.” Arthritis and Rheumatism.  
 2011 Nov 29. DOI: 10.1002/art.33459. [Epub ahead of print]. 
 
 
The copyedited version is expected to be out in print in April 2012. 
 
 
     4
Table of Contents 
Introduction 
 Rheumatoid Arthritis: Pathogenesis 5 
 Rheumatoid Arthritis: A review of known immunopathology 8 
 Rheumatoid Arthritis: A review of treatment modalities 11 
 Peri-implant Osteolysis 13 
 Purpose of Present Study  17 
 Aims of Study  18 
Patients and Methods 
 Identification of Patients 19 
 Device Evaluation 19 
 Histopathology  20 
 Osteolysis  23 
 Statistical Analysis 23 
 Contributions to Present Study 23 
Results   
 Profile of Patients 25 
 Biomechanical Wear 27 
 Histopathologic Analysis 27 
  a) Particulate Debris 27 
  b) Tissue Reaction 30 
  c) Extent of Inflammatory Reaction 30 
  d) Immunohistochemistry 33 
 Radiographic Analysis 33 
 Inter/Intra-rater reliability of Statistical Methods 34 
Discussion  35 
Limitations  40 
Future Directions  41 
References  43 
 
 
     5
Introduction 
Rheumatoid Arthritis: Pathogenesis 
Rheumatoid arthritis (RA) is a common systemic autoimmune disorder, with an estimated 
population prevalence of 1%. It is characterized by persistent chronic inflammation, 
which classically destroys the tissue and bone of diarthrodial joints, but also has multiple 
systemic manifestations[1, 2]. The currently understood pathophysiology of RA is 
multifaceted, involving a genetically encoded predisposition towards an aberrant 
inflammatory response to both external and internal stimuli. 
 The post-translational modification known as citrullination facilitates an 
autoimmune pathway that is thought to be a key pathophysiologic mechanism of RA. The 
susceptibility to forming citrullinated proteins is most consistently linked with a genetic 
predisposition in the HLA-DRB1 gene[3]. This gene is responsible for producing MHC 
class II molecules involved in the presentation of peptides during the initiation of an 
immune response. However, aberrant alleles at this locus, especially HLA-DRB1*04, 
have been shown to create peptide-binding epitopes that preferentially bind citrullinated 
proteins generated from self-antigens [4, 5]. Recognition of these auto-antigens then 
precipitates a systemic autoimmune response. This response results in the formation of 
antibodies against citrullinated proteins that is clinically measured by the presence of 
anti-CCP (anti-cyclic citrullinated peptide) antibodies[3]. The current literature suggests 
that anti-CCP positivity and negativity represent two distinct subsets of rheumatoid 
arthritis[5-7]. 
 Anti-CCP positive RA stems from both exogenous and endogenous factors, which 
stimulate an autoimmune response towards citrullinated proteins. For example, 
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citrullinated fibrinogen and vimentin have been used in the literature to elicit an 
autoimmune response through the HLA-DR1 shared epitope allele. Van de Woude et. al. 
showed that in the presence of HLA-DR1 and a smoking history, antibodies directed 
against vimentin conferred an odds ratio of 58 for RA compared to an odds ratio of 5.4 in 
the absence of these antibodies [6]. These ratios were much closer in patients with 
antibodies against fibrinogen[6]. Antibodies directed against citrullinated vimentin, 
fibrinogen, and alpha-enolase in particular show limited cross-reactivity. Antibodies 
against type II collagen appear to form in the absence of citrullination but again show 
limited reactivity against other antigens. Positivity toward each of these possible triggers 
appears to represent distinct subgroups of anti-CCP positive RA [5]. Such studies 
indicate that a combination of genetic risk factors, environmental risk factors such as 
smoking, and the presence of various citrullinated peptides together dictate the extent of 
an autoimmune response that is linked to rheumatoid arthritis.  
 However, where these peptides come from or what causes them to form is less 
clear. Snir et. al. demonstrated in RA patients that anti-CCP antibodies were present at 
higher levels in the synovial fluid compared to the serum when compared to tetanus 
toxoid controls, which were significantly higher in the serum. This point raises the 
possibility that anti-CCP antibodies are locally produced at the site of inflammation and 
rheumatologic disease [3, 5, 8]. Other studies have demonstrated ectopic lymphoid 
structures and the presence of clonal B cell aggregates in the synovial tissue of RA 
patients [3, 8]. Such findings are consistent with the production of anti-CCP antibodies 
within the RA synovium. 
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 Furthermore, alpha-enolase is a glycolytic enzyme that has been found in the 
joints of patients with multiple types of inflammatory arthritis. Citrullinated alpha-
enolase (CEP), however, has been associated more with RA, leading to an interest in anti-
CEP antibodies as a more specific subset of anti-CCP antibodies for disease detection. 
One study indicated that anti-CEP antibodies have up to a 97% specificity for RA [9]. 
Mahdi et. al. recently published a study linking the presence of CEP to smoking. The 
mechanism of this process is unclear but smoking has also been independently associated 
with anti-CCP positivity[9]. The formation of anti-CEP antibodies is associated with the 
BRD 2 gene [9]. Studies also show that the concurrent presence of the HLA-DR1 shared 
epitope, a smoking history, and the PTPN22 gene is linked to anti-CEP positivity[3]. 
 Comparatively less can be surmised about the pathogenesis of anti-CCP antibody 
negative RA. Though prior studies had indicated that the HLA-DR1*03 locus is 
associated with the autoantibody negative subset of RA, more recent studies have not 
found a statistically significant association[10]. A recent study looked at a genome-wide 
association of both HLA and non-HLA genes in RA patients with and without anti-CCP 
antibody positivity. The most significant difference between antibody positive and 
negative patients was on chromosome 6 in the HLA region. Of note, two non-HLA genes 
associated with anti-CCP antibody negative RA were identified: rs4305317 and 
rs6448119. The former is considered to be the best candidate gene with specificity for 
anti-CCP antibody negative RA [7]. However, before insight can be gained into this 
subset of RA, further studies corroborating the identification of this candidate gene are 
needed. 
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Rheumatoid Arthritis: A review of known immunopathology 
 As a disease entity whose pathogenesis involves autoantibody production by 
plasma cells, RA mediates inflammation by involving components of both the innate and 
adaptive immune system. 
 The initial phase of RA involves the formation of a pannus in the RA synovium. 
This formation consists of monocytes and fibroblasts whose infiltration into the 
synovium is facilitated by matrix metalloproteinases produced by the synovial lining 
cells. The pannus eventually becomes slightly vascularized and is covered by collagen. 
The tissue from which the pannus originates is thought to arise from type B 
synoviocytes[2]. 
 Unlike other inflammatory diseases in which non-specific inflammation pervades 
the tissue, RA is often characterized by well-structured arrangements of inflammation. 
These well-developed ectopic germinal centers are present in the RA synovium, contain 
both T and B cells, and represent one of the most striking features of RA[1, 8]. Prior 
experiments have examined how T cells function in these germinal centers by comparing 
CD4+ T cell clones from the follicles of RA synovium to control CD4+ T cell clones 
from the peripheral blood [1]. Specifically, the output of cytokines was measured in 
response to fragments of RA synovium that were peripherally injected in a mouse model. 
The result was a multi-fold increase in the output of cytokines such as IFN- γ, IL-1β, and 
TNF-α in mice with follicular T cells. Interestingly, however, the production of these 
cytokines by CD4+ T cells was dependent on the presence of B cells, implicating B cells 
in T cell activation[1]. 
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 Furthermore, follicular dendritic cell networks comprise the aforementioned 
germinal centers in addition to T and B cells. Studies suggest that in the presence of these 
dendritic cell networks, activation-induced cytidine deaminase (AID) is also present[8]. 
AID is an enzyme required for class switching and hypermutation of immunoglobulins as 
they develop an affinity for particular antigens within CD21+ germinal centers. In 
addition, levels of AID within T or B cell aggregates correlated directly with anti-CCP 
antibody levels in the RA synovial tissue. This finding suggests that AID is associated 
with the formation of these antibodies, though a causative role has not been formally 
elucidated[8]. This study also corroborates that plasma cells in the germinal centers of 
RA patients do produce self-reacting antibodies as detected by anti-CCP antibody levels. 
 In addition, studies have documented the presence of IL-17 producing T cells 
(Th-17 cells) in RA synovial fluid. The quantitative levels of IL-17 were significantly 
greater in RA synovial fluid compared to both OA synovial fluid and RA peripheral 
blood samples [11]. Since IL-17 is thought to play a role in the inflammatory process 
leading to destruction of synovial tissue, bone, and cartilage, the finding that IL-17 
producing CD4+ lymphocytes can be isolated from RA synovial tissues is 
significant[11]. In addition, observations suggest that IL-27 is involved in the 
differentiation of Th-17 cells while IFN- γ plays a role in Th-17 cell polarization, 
implicating two other cytokines in the potentiation of IL-17 activity. IL-23 has also been 
previously identified in the synovial tissue of RA patients but there is no conclusive 
evidence for its role in promoting Th-17 cell proliferation[11]. 
 While CD4+ T lymphocytes have been traditionally considered the primary 
source of IL-17, recent studies suggest a role of the innate immune system in producing 
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IL-17. Specifically, mast cells in inflamed RA synovial tissue are often triggered by 
inflammatory stimuli such as complement, TNF-α, or autoantibodies to produce IL-
17A[12]. Hueber et. al. also showed not only that mast cells have a likely role in RA 
pathogenesis, but also that the role of T lymphocytes in promoting inflammatory arthritis 
through mediation of IL-17 might be less than previously thought. In samples of RA 
synovial tissue, CD3+ cells (T cell marker) accounted for only 1-8% of IL-17A 
producing cells compared to 46-100% colocalization of MCT (mast cell marker) and IL-
17A production [12]. This finding, however, does not imply that T lymphocytes in 
germinal centers do not mediate synovial inflammation through other pathways. 
 While many individual cytokines and chemokines have been implicated in 
downstream pathways that lead to the inflammation and tissue destruction of RA, recent 
studies have focused on TNF-α. TNF-α has been described for the past 25 years as a 
potential single mediator of RA, with specific attention paid to its presence in the 
synovial tissue, role in mediating both pro-inflammatory and anti-inflammatory 
cytokines, and even upregulation of TNF receptors in RA[13]. Clinical trials that initially 
compared anti-TNF therapy to placebo controls in the mid-1990’s demonstrated a 79% 
response rate with anti-TNF therapy as measured by a Paulus 20% response, compared to 
an 8% response in placebo controls[13, 14]. A Paulus 20% response is defined as a ≥20% 
improvement in at least 4 of the following 6 areas: joint tenderness, joint swelling, 
patient’s global assessment of improvement, physician’s global impression of 
improvement, morning stiffness, and ESR [15]. Given this clinical benefit, further studies 
have focused on the role of TNF-α in the pathogenesis of RA particularly because of its 
potential as a therapeutic target. Apart from its well-demonstrated role in mediating 
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inflammation, which in turn is associated with synovial tissue destruction, TNF-α has 
been shown to affect angiogenesis, leukocyte trafficking, and hematologic cell lines, all 
of which can have systemic effects[13]. 
 
Rheumatoid Arthritis: A review of treatment modalities 
 As demonstrated in the previous sections, the pathogenesis of rheumatoid arthritis 
revolves around an aberrant immune response to self-antigens. That immune response 
involves extensive cytokine cascades, antibody production, and the local destruction of 
bone and tissue due to organized centers of inflammation. As a result, the basic principle 
of managing RA revolves around reducing inflammatory mediators. Though the approach 
is typically systemic, given the diffuse nature of inflammatory arthritis as well as the 
capacity of RA to produce extra-arthrodial disease, therapy has varying levels of 
specificity. 
 Prior to the mid 1990’s, the initial approach to treatment of RA involved steroids 
or NSAIDs until disease progression necessitated more potent anti-inflammatory 
medications known as DMARDs (disease-modifying anti-rheumatic drugs) [2]. However, 
subsequent studies indicated that early initiation of DMARDs in recently diagnosed RA 
patients resulted in improved outcomes at multiple endpoints including ESR levels, pain, 
and joint mobility [2, 16]. 
 DMARDs have varying mechanisms of action but all mitigate inflammation either 
by preventing the proliferation and development of cells involved in inflammation or by 
neutralizing the inflammatory mediators produced by such cells. They can be broadly 
classified as either synthetic (most commonly methotrexate or leflunomide) or biological 
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(most commonly etanercept, adalimumab, or infliximab)[17]. Biological DMARDs are 
also referred to as anti-TNFα agents or biologics.  
 The American College of Rheumatology (ACR) recommendations as of 2008 
suggested immediate initiation of methotrexate or leflunomide in all patients diagnosed 
with RA regardless of disease duration or severity[18]. Other less common synthetic 
DMARDs such as hydroxychloroquine or sulfasalazine were recommended if poor 
prognostic factors existed. Poor prognostic features were defined as including “functional 
limitations, extra-articular disease, RF positivity +/- anti-CCP positivity, and/or bony 
erosions by radiography”[18].  
 Per the ACR, use of biological DMARDs hinges more on the duration of disease. 
In patients with disease duration <6 months, the recommendation is for methotrexate 
along with a biologic only in patients with high disease activity. Patients with RA for 
longer than 6 months who failed prior methotrexate monotherapy, who have severe 
disease, or who have moderate disease but a poor prognosis were candidates for anti-
TNFα agents[18].  
 Biologic DMARDs have been shown to be more efficacious when used as 
monotherapy compared to both methotrexate and placebo controls[19]. The relative 
effect of combination therapy is, however, unclear. Combining methotrexate with an anti-
TNFα agent resulted in better clinical and functional outcomes when compared to 
monotherapy in some studies[17]. Subsequent studies indicate the improved efficacy 
conferred by combination therapy might be particularly true for patients who have failed 
methotrexate therapy as compared to methotrexate-naïve patients[19]. The current ACR 
recommendations acknowledge foremost the effectiveness of biologics, citing that they 
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are “efficacious in improving disease activity, function, and quality of life and/or 
retarding radiographic progression [of disease] when used alone, in combination with 
methotrexate, or in patients for whom treatment with DMARDs other than methotrexate 
led to an inadequate response” [18]. 
 Furthermore, apart from lowering serum levels of pro-inflammatory cytokines, 
anti-TNFα agents can secondarily help in RA. Infliximab, which is a monoclonal 
antibody directed against TNFα, has been shown to lower CRP levels, thereby lowering 
levels of downstream complement activation. Complement activation has been previously 
linked to the pathogenesis of RA in animal models[20]. 
 When considering adverse events associated with anti-TNF therapy, the most 
common concern is infection[21]. Infliximab, in particular, has been associated with a 
higher incidence of severe infection[19]. Multiple studies have raised the possibility of 
etanercept being linked to a higher incidence of malignancy, including lymphoma and 
skin cancer. However, no statistically significant association exists, including in a meta-
analysis of more than 3300 patients [19, 21, 22]. There is limited evidence from clinical 
trials suggesting that newer biologics such as abatacept and rituximab might have more 
favorable safety profiles, though this is far from conclusive[21]. 
 
Peri-Implant Osteolysis 
 Despite the reviewed understanding of the natural history of RA as well as 
management strategies that target its immunologic pathophysiology, the disease and its 
optimal management have not been fully characterized in patients with arthroplasties. 
When joint destruction related to the severity of disease necessitates a prosthetic implant, 
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RA patients not only have to deal with their underlying inflammatory arthritis but also the 
body’s response to an implant. 
 Orthopedic interventions are relatively common in RA patients. Of 183 RA 
patients who were followed for 16-20 years in a prospective study, 58% underwent some 
form of orthopedic surgery and 24% had a joint replacement. Arthroplasties of all major 
joints were noted with hips and knees being the most common, but non-weight bearing 
joints such as elbows, shoulders, wrists, and fingers together represented 36% of the 
arthroplasties performed [23]. A prosthetic joint has multiple components. It typically 
consists of two metal stems that are inserted into each of the two bones forming a joint. 
These metal stems are often cemented in place and are joined with metal axles, using 
polyethylene bushings as a lubricating surface. 
 From a biomechanical perspective, the polyethylene bushings absorb great 
amounts of impact and are vulnerable to deterioration over time. In elbow arthroplasties, 
for example, Lee et. al. found that the polyethylene bushings had to be replaced at an 
average of 7.9 years[24]. Goldberg et. al. also found that the ulnar and humeral 
polyethylene bushings found in total elbow arthroplasties are the weakest components of 
the device[25].  As the implant is in place for an extended period of time, the 
polyethylene surface is slowly deformed leading to loss of microscopic pieces of 
polyethylene into the tissue surrounding the arthroplasty. If enough of the polyethylene 
lubricating surface is deformed, the metal components of the implant eventually articulate 
causing pieces of metal debris to also spread into the peri-prosthetic tissue. 
 Numerous studies have demonstrated that both polyethylene and titanium metal 
particles in the peri-prosthetic tissue are linked to osteolysis, or loss of peri-implant bone, 
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which in turn causes aseptic loosening of the arthroplasty. Initial models suggested three 
potential mechanisms for wear debris-induced inflammation that bring about destruction 
of bone[26].  
 First, macrophages activated by the phagocytosis of particulate debris have been 
shown to generate nitric oxide. Such free radicals in turn worsen inflammation in the 
joint tissue and facilitate the activation of osteoclastic differentiation and enzymatic 
activation[26]. Initial studies indicated that titanium alloy had the largest effect in 
stimulating nitrite production in a mouse model, likely through upregulation of inducible 
nitric oxide synthase. Pure titanium metal and polymethylmethacrylate showed slightly 
lower levels of nitrite production[27].  
 Second, Wang et. al. demonstrated that exposure of bone marrow cells to foreign 
body wear debris over time causes a decrease in mesenchymal stem cells’ (MSC) ability 
to differentiate into osteoblasts. The mechanism through which titanium particles in 
particular suppress osteoblastic differentiation appears to hinge on suppression of the 
BSP gene[26]. Third, titanium particles have also been linked to promoting apoptosis of 
MSC’s. Mechanisms of reduced MSC viability include p53-mediated apoptosis and 
activation of death receptors by TNFα[26]. 
 While many of the previously noted studies suggest a significant role for titanium 
metal in bringing about osteolysis, polyethylene has been extensively linked to aseptic 
loosening as well. Numerous studies suggest that the tissue reaction to polyethylene 
debris depends on the size and manufacturing properties such as cross-linking [28]. The 
mechanism of polyethylene-induced osteolysis is postulated to be similar to titanium 
metal particles in that macrophages activated by the phagocytosis of particles bring about 
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a release of pro-inflammatory cytokines, including TNFα. These cytokines in turn 
upregulate matrix metalloproteinases as well as RANK and RANK ligand, which directly 
increase osteoclastic differentiation and proliferation leading to osteolysis[28, 29]. At the 
same time, bone formation is uncoupled from resorption such that apoptotic pathways 
preferentially promote the survival of osteoclasts and death of immature osteoblasts, 
largely through the action of TNFα [28, 30, 31]. The dose-dependent preference of 
apoptotic pathways for immature over mature osteoblast lineages has been specifically 
demonstrated in vitro[31]. 
 Although the role of the innate immune system in responding to foreign body 
wear debris has been well described, the role of the adaptive immune system is less 
certain. Willert et. al. described the presence of a lymphocytic infiltrate in the peri-
prosthetic tissue of patients with metal-on-metal hip implants that had resulted in aseptic 
loosening[32]. Goldberg et. al. examined the peri-articular tissue taken during revision of 
a total elbow arthroplasty for aseptic loosening due to osteolysis. While this study noted a 
robust giant cell and histiocytic response, 69% showed a minimal lymphocytic response 
and 12% showed a significant lymphocytic response[25]. Hallab et. al. showed a Th1 
lymphocytic response was detected in response to a metal challenge test in patients with 
total hip arthroplasties. An increase in IFN- γ, which is released by Th1 lymphocytes and 
is associated with osteoclast activity, supports this claim. The emergence of a subset of T 
lymphocytes indicates a level of specificity consistent with an adaptive immune response 
to metallic debris[33]. While some studies have also postulated how RANKL expression 
on the surface of T cells is sensitive to TNFα and might also promote osteolysis, other 
studies have shown no osteolysis in lymphocyte-deficient mice[30, 34]. 
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Purpose of Present Study 
 Peri-implant osteolysis and associated loss of fixation is the major reason total 
joint replacements fail.  The progressive loss of bone adjacent to the implant has been 
attributed to a granulomatous inflammatory reaction induced by particulate implant wear 
debris at the bone-implant interface [35]. Patients frequently exhibit dramatic differences 
in the rate of peri-implant bone loss, and it is unclear whether this reflects differences in 
the properties or amount of wear debris, differential patterns of biomechanical failure, or 
differences in individual host immune response.  
 This distinction regarding the underlying mechanism driving aseptic loosening is 
particularly critical in patients who are already susceptible to an overblown inflammatory 
response, as occurs in RA. RA patients with arthroplasties respond to both the baseline 
inflammatory properties of particulate debris, and the organized inflammation and joint 
destruction characteristic of this inflammatory arthritis. 
 Studies by Caplan and coworkers noted that coal miners with RA who were 
exposed to silica containing coal dust were uniquely prone to the development of large 
pulmonary granulomas (“Caplan’s nodules”) [36].  They speculated that this differential 
response to an inorganic particulate reflected an intrinsic alteration in immunoregulation 
among RA patients.  Similarly, RA patients may exhibit a unique immune response to the 
inorganic wear particles generated by prosthetic implants, which might lead to different 
failure mechanisms compared with non-RA patients.  
 Kaufman et. al. reported on a series of patients undergoing revision surgery for 
aseptic failure after TEA [37].They did not note a difference in the cellular features of the 
peri-implant tissue reaction in patients with or without inflammatory arthritis. More 
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recently, Goldberg et. al. evaluated the tissue reaction accompanying failed, semi-
constrained, Coonrad-Morrey elbow implants at primary revision in sixteen patients, nine 
of whom had inflammatory arthritis [25]. Similarly, the peri-prosthetic tissue showed no 
evidence of a differing cellular reaction on the basis of underlying diagnosis. In contrast, 
Goldring et. al. found that among a similar group of patients, lymphoplasmacytic 
inflammation was found exclusively in RA patients [38]. Factors responsible for these 
contradictory findings could include differences in the composition and types of devices, 
differences in patient populations, and differences in treatment. 
 
Aims of Study 
The present study was undertaken to compare cellular features of the peri-implant tissue 
response among patients with and without RA undergoing revision of a TEA due to 
aseptic loosening, and to ascertain the relationship with underlying disease, patterns of 
gross device wear, and the amount and type of particulate debris. 
 
 
 
 
 
 
 
 
 
     19
Patients and Methods 
Identification of Patients 
Surgical specimens from all primary TEA revisions performed between 1996 and 2008 
for aseptic loosening were identified from the database of the Department of Pathology 
and Laboratory Medicine at the Hospital for Special Surgery (HSS). Given that the elbow 
is a non-weight bearing joint, this population is not predominated by degenerative joint 
disease and is, therefore, enriched for RA patients. Implant components corresponding to 
the identified cases were recovered through the Implant Retrieval Registry in the 
Hospital’s Department of Biomechanics. The patients’ primary diagnosis, gender, race, 
age at primary TEA, age at revision TEA, pre-revision medical treatment, pre-revision 
flexion-extension range of motion, dominant hand, as well as height and weight at the 
time of revision were obtained from medical records. Non-RA patients include non-
inflammatory arthritis patients with a history of OA or trauma.  RA patients were labeled 
treated or untreated based on pre-operative usage of a TNF-inhibitor. When stratifying 
patients on this basis, those in whom this data was unavailable were excluded from 
analysis. Duration of implantation was defined as the number of years between the 
original TEA and primary revision TEA. A short duration of implantation was <4 yrs; a 
long duration of implantation was ≥ 4 yrs. HSS Institutional Review Board approval was 
obtained for this study. 
 
Device Evaluation 
 As available, the retrieved humeral and ulnar components, humeral polyethylene 
bushing (Fig. 1A), and axle were evaluated for evidence of wear and surface damage. 
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Due to the limited number of metal components (Fig. 1B), no information was collected 
on metal loss. 
 A previously developed subjective scoring method was used to assess seven 
modes of polyethylene damage [39]. Of the seven modes, conformational change, due 
either to deformation or material loss, was considered the most accurate and functionally 
relevant metric of biomechanical damage. Grades of none, mild, moderate or severe 
corresponded with 0, <10%, 10-50%, and >50% of the articulating surface area being 
visually thinner than the non-articulating surface. However, this scoring system was 
insufficient to estimate the extent of wear in instances of penetrating focal damage. Focal 
wear was measured separately as the proportion of thinning in a localized area between 
the inner and outer bushing diameters compared to a non-deformed region.  Focal wear 
was graded as none, mild, moderate, or severe corresponding to the diameter being 0, 
<10%, 10-50%, and >50% thinner compared with the non-deformed surface. A device’s 
final grade was the highest qualifying score on the basis of either surface area damaged 
or focal wear.  
 All grading was done under a stereomicroscope while blinded to both the 
underlying diagnosis and tissue histology. Grading was performed independently by two 
readers (AV and DC). Differences were resolved by consensus. 
     
Histopathology 
Hematoxylin and eosin stained samples of peri-prosthetic tissue were evaluated for the 
type and size of particulate material, as well as the presence, type, location, and intensity 
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of inflammatory infiltrates. This analysis is based on a modification of a similar analysis 
published elsewhere [40].  
 Polyethylene debris particles were classified as either small (<500µm) or large 
(≥500 µm) based on the largest dimension (Fig. 1C). Metal particles were not stratified 
by size, as they were uniformly small particles (~10µm) with little heterogeneity on the 
basis of visual identification.  The distribution of polyethylene debris was defined as low 
prevalence or high prevalence. Low prevalence was defined as wear particles seen in 
≤50% of the area of at least 2 histologic fields viewed at 10x magnification. For metallic 
debris, which was less common, low prevalence was defined as particles seen in ≤10% of 
the area of at least 2 histologic fields viewed at 10x magnification. 
 In describing the peri-prosthetic tissue reaction, monocytes and giant cells were 
defined as low prevalence if they comprised ≤ 50% of the cellular infiltrate on two 
separate 10x fields, and high prevalence if they comprised >50%.  A lymphocytic 
aggregate was defined as a group of ≥10 lymphocytes visualized on a 5x field. 
Perivascular infiltrates surrounded a discernable vascular structure (Fig. 1D). Focal 
interstitial infiltrates were defined as aggregates of lymphocytes in the absence of a 
discernable vascular structure (Fig. 1E). Sheet-like aggregates were defined as a diffuse 
interstitial pattern of lymphocytic infiltrates throughout the entire tissue section (Fig. 1F). 
Focal interstitial and sheet-like aggregates represent two degrees of intensity of 
interstitial lymphocytic inflammation. When evaluating plasma cells within lymphocytic 
aggregates, low prevalence of plasma cells was defined as comprising ≤ 10% of the 
lymphocytic aggregate, and high prevalence >10% of the aggregate in two separate 10x 
fields.  
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 To confirm that our histologic identification of cell types was correct, 
immunohistochemistry was performed on tissue from a representative subset of cases. T- 
and B-lymphocytes were identified by using anti-CD3 and anti-CD20 antibodies, 
respectively, and plasma cells by using anti-Kappa and anti-Lambda antibodies. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
A B 
D 
E F 
Figure  1. A.) Humeral polyethylene bushing showing focal, severe conformational change (thin arrow). 
Moderate conformational change present on the opposite end of bushing (thick arrow). B.) Moderate 
metal loss on the proximal portion of the humeral stem (white arrow). C.) Small particulate polyethylene 
of high prevalence shown in polarized light at 10x. D.) Perivascular lymphocytic inflammation (40x) E.) 
Interstitial lymphocytic inflammation (40x) with visible plasma cells (thin arrow). Metallic debris being 
phagocytosed by foreign body giant cells (thick arrow). F.) Sheet-like lymphocytic infiltration with 
widespread plasma cells (thick arrow) at 40x. Metallic debris present across entire field (white star). 
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Osteolysis 
Available anterior-posterior (AP) and lateral pre-operative radiographs were evaluated 
for the presence of osteolysis based on a previously used scoring system [25]. The 
humeral and ulnar stems of the prosthetic were divided into 4 zones each and examined 
for the presence of radiolucencies at both the cement-prosthesis and cement-bone 
interface.   
 
Statistical Analysis 
Fisher’s Exact test was used to compare all categorical variables. Sample size made this a 
more high fidelity test than Chi-squared. T-tests were performed on continuous data. A 
kappa analysis was performed to establish inter- and intra-rater reliability of the 
qualitative histologic scoring. 
 
Contributions to Present Study 
 Primary responsibility for all data collection, compilation, and analysis was held 
by Anant Vasudevan. Dr. Lisa Mandl was the principal investigator who oversaw and 
contributed to all progress in data collection, analysis, and communication of results. 
Anant Vasudevan, Dr. Mandl, and Dr. Goldring shared responsibility for study design, 
analysis of data, and interpretation of results. In examining devices, Dan Chen and Anant 
Vasudevan shared equal responsibility in grading all aspects of implant wear. Dr. Wright 
aided in the design of parameters through which to assess devices and provided opinions 
as needed. In examining histology samples, Dr. DiCarlo provided expert qualitative 
impressions of both particle burden and the extent of the inflammatory tissue reaction to 
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wear debris. Anant Vasudevan and Dr. DiCarlo examined all histopathology slides and 
collected all data together. Immunohistochemical analysis of histology samples was 
performed commercially. The chart review was performed by Anant Vasudevan. In 
assessing osteolysis, Anant Vasudevan helped assemble the parameters for evaluating 
radiographs, and Dr. Figgie, an orthopedic surgeon, provided expert reads of films. 
Statistical analysis was performed by Anant Vasudevan except the kappa analysis for 
inter/intra-rater reliability, which was done by Dr. Stephen Lyman of the HSS 
Biostatistical Core. All authors contributed to revising the Methods, Results, and 
Discussion sections of this manuscript. 
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Results 
Profile of Patients 
Of 88 cases, 11 were excluded because of infection. Of the remaining 77 cases, 39 had 
inadequate tissue for review. Complete medical records were available in 36 of the 
remaining 38 patients; two had only the operative record and partial medical records. 
 Twenty-five of the 38 patients had RA (66%), 7 had OA (18%), and 6 had a 
history of traumatic elbow injury without underlying inflammatory arthritis (16%). Of the 
25 RA patients, 24 had pre-operative medication data. Ten RA patients were on a TNF 
inhibitor pre-operatively (etanercept in all cases). The remaining 14 RA patients were not 
on a TNF inhibitor pre-operatively. None of the non-RA patients were pre-operatively on 
a TNF inhibitor. 4 patients (3 RA and 1 non-RA) underwent revision surgery prior to 
FDA approval of etanercept. 
 Of all RA patients, 91% were Caucasian, 84% were women, and 95% were right-
handed compared to 100%, 87%, and 100% respectively in non-RA patients. The right 
elbow was the operative site in just under half of both groups. Thirteen percent of RA 
patients and 33% of non-RA patients had a BMI >30 (p = 0.19). The average pre-
operative range of motion was 112° (0 to 210°) for RA patients and 109° (60 to 130°) for 
non-RA patients (p = 0.85). RA patients were younger at the time of original implant 
surgery (p=0.0003). The average duration of implantation was 8.9 yrs for all RA patients 
and 5.3 yrs for non-RA patients (p = 0.06) (Table 1).  
 Untreated RA patients had a longer time to primary revision than treated RA 
patients (10.9 vs. 5.8 yrs, p = 0.04) or non-RA patients (10.9 vs. 5.3 yrs, p = 0.01). There 
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was no difference in the duration of implantation between non-RA patients and treated 
RA patients (5.8 vs. 5.3 yrs; p = 0.77). 
 
RA: 25 Non-RA: 13 (7OA, 6 Trauma) P-value 
Female 84% 87% 1.0 
Race (N = 23) (N = 13) 1.0 
    Caucasian 91.3% 100%  
    Black 4.3% 0%  
    Asian 4.3% 0%  
 
Avg. Age at Original 
Implant 
50.8 ± 12.3 yrs (N = 24) 66.1 ± 8.1 yrs 0.0003 
 
Avg. Age at First    
       Revision 
58.3 ± 15.0 yrs 71.4 ± 6.8 yrs 0.005 
 
Duration of 
Implantation 
8.9 ± 5.8 yrs 5.3 ± 4.3 yrs 0.06 
 
Range of Motion     
(Flex-Ext) 
112.2° (N = 20) 108.9° (N = 8) 0.85 
 
Index Elbow 
 
44% Right Elbow 
 
46% Right Elbow 
 
1.0 
 
Dominant Hand 
 
     95% right-handed 
(N = 19) 
 
100% right-handed 
(N = 13) 
1.0 
 
BMI (< 30 vs. ≥ 30): 
 
(N = 24) 
 
(N = 12) 
 
0.19 
    18.5 – 24.9 13 5  
    25.0 – 29.9 8 3  
    ≥ 30.0 3 4  
 
DMARDS: 
 
(N = 24) 
 
(N = 12)  
    Etanercept 10 0  
        + Methotrexate 3 -  
        + Imuran 1 -  
 
Bisphosphonates 
 
3 
 
4 
 
0.40 
Prednisone 6 0 0.28 
 
Table 1. Descriptive statistics on 38 TEA patients. 25 RA and 13 non-RA patients used for each variable unless otherwise indicated. 
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Biomechanical Wear 
 Of the 38 patients in this study, 24 had semi-constrained retrieved implants 
available for analysis. Twelve of the implants were Osteonics Linked Semiconstrained 
replacements manufactured by Osteonics, 7 were Coonrad-Morrey implants 
manufactured by Zimmer, 2 were Solar devices manufactured by Stryker, 2 were Triaxial 
prostheses manufactured by Johnson and Johnson, and 1 was a custom device. All 
devices had humeral polyethylene bushings. Metal components were available for 15, of 
which 3 contained both humeral and ulnar components, 7 contained only the humeral 
component, and 5 contained only the ulnar component. Five of the axle-containing 
devices had no axle available for analysis. All metal components were titanium. 
 Conformational changes in the 24 humeral polyethylene bushings were mild in 
10, moderate in 3, and severe in 11. Moderate changes were qualitatively much closer to 
severe than mild, so moderate and severe categories were grouped for statistical analysis. 
No difference in severity of conformational changes were noted between Coonrad-
Morrey implants and other designs (p = 0.08). More severe conformational change was 
associated with a longer duration of implantation of >4 years (p = 0.01). Conformational 
change showed no association with underlying diagnosis (RA vs. non-RA, p = 1.0), or 
with use of TNF inhibitors (p = 1.0) (Fig. 2A), regardless of whether the 3 instances of 
moderate changes were excluded.  
Histopathologic Analysis 
a) Particulate Debris 
 Polyethylene and metal particles were observed in varying quantities in the peri-
prosthetic tissue reaction. Increased polyethylene particle prevalence (p = 0.01) and size 
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(p = 0.005) and increased metal particle prevalence (p=0.05) were all associated with 
more severe conformational change (Fig. 2B-D). 
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Figure 2. A.) Degree of conformational change, adjusted for cases of focally 
severe damage, did not vary with underlying diagnosis or use of anti-TNF 
therapy. Severe conformational change in the humeral polyethylene bushing 
is associated with higher polyethylene particle prevalence (B), larger 
polyethylene particle size (C), and a trend towards higher metal particle 
prevalence (D). 
 
  p = 0.005 
  p = 0.05 
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 Increased polyethylene particle prevalence (p = 0.06) and increased polyethylene 
particle size (p = 0.03) were associated with duration of implantation > 4 yrs.  Metal 
particle prevalence was not associated with duration of implantation (p = 0.15). 
 No difference was found in the prevalence or size of polyethylene particles among 
non-RA patients, treated RA patients, or untreated RA patients (p ≥ 0.65 for all 
comparisons) (Fig. 3A-B). Similarly, no difference existed in the prevalence of metal 
particles among these three groups (p ≥ 0.68) (Fig. 3C). 
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Figure 3. Prevalence of polyethylene particles (A), size of polyethylene 
particles (B), and prevalence of metal particles (C) did not vary with 
underlying diagnosis or anti-TNF therapy. 
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b) Tissue Reaction: 
 A higher prevalence of foreign body giant cells was associated with a higher 
prevalence of polyethylene particles (p < 0.001), larger polyethylene particles (p = 
0.004), and higher prevalence of metal particles (p = 0.04). There were no significant 
differences in the prevalence of foreign body giant cells (p = 0.73) between non-RA 
patients and RA patients. This finding did not change when RA patients were stratified 
by use of anti-TNF therapy (p = 1.0). 
 No association was found between the prevalence of monocytes and the 
prevalence of polyethylene particles (p = 0.24), size of polyethylene particles (p = 0.25), 
or prevalence of metal particles (p = 1.0). There were no significant differences in the 
prevalence of monocytes (p = 0.12) between non-RA patients and RA patients. This 
finding did not change when RA patients were stratified by use of anti-TNF therapy (p = 
1.0). 
 The presence of any lymphocytic aggregates was associated with lower metal 
particle prevalence (p = 0.005) but not with polyethylene particle prevalence (p = 0.14) or 
size (p = 0.32). An increased plasma cell prevalence within lymphocytic aggregates was 
associated with widespread metal particles (p = 0.049) but was not significantly 
associated with polyethylene prevalence (p = 0.36) or size (p = 0.40). 
c) Extent of Inflammatory Reaction: 
 In the presence of any type of wear debris, untreated RA patients showed an 
interstitial pattern of lymphocytic aggregation as opposed to the predominantly 
perivascular pattern seen in non-RA patients (p = 0.04). Treated RA patients showed a 
mixed pattern of perivascular and interstitial lymphocytic infiltrates intermediate between 
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non-RA patients and untreated RA patients (Fig. 4A). 50% of untreated RA patients also 
showed a sheet-like intensity of lymphocytic infiltrates compared to none of the non-RA 
patients (p = 0.09). Treated RA patients showed a mixed intensity of lymphocytic 
infiltrates with 22% being diffuse, sheet-like infiltrates. 
 A similar pattern of lymphocytic infiltration was seen when considering only 
patients with small or few wear particles of any type. The majority of these patients had 
≤10% plasma cells in the lymphocytic aggregates, with no significant difference when 
comparing underlying diagnosis, treatment, or particle composition. 
 Among patients with a high prevalence of polyethylene debris, including small 
and large particles, all untreated RA patients showed lymphocytic infiltrates with an 
interstitial or diffuse sheet-like appearance, associated with a high prevalence of plasma 
cells. This pattern was present in only half of treated RA patients.  Only one non-RA 
patient exhibited this pattern of polyethylene debris, and in this patient the lymphocytic 
aggregates were perivascular and associated with a low prevalence of plasma cells (p 
=0.33) (Fig. 4B). The cellular patterns were similar in tissue sections containing 
predominantly large non-phagocytosable polyethylene particles (Fig. 4C). Again, all 
untreated RA patients had a high prevalence of plasma cells in lymphocytic infiltrates 
compared with none of the non-RA patients (p = 0.07). Only one-third of treated RA 
patients exhibited this pattern. 
 In the presence of a high prevalence of metal debris, untreated RA patients had 
exclusively lymphocytic aggregates with an interstitial or sheet-like appearance that were 
associated with a high plasma cell prevalence (Fig. 4D).  Unlike the histologic findings 
associated with polyethylene, 40% of the non-RA patients had lymphocytic aggregates 
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with high plasma cell prevalence; however, unlike the RA patients, the plasma cells were 
associated with focal interstitial or perivascular lymphocytic aggregates. Treated RA 
patients had a prevalence of plasma cells similar to the non-RA patients (p = 1.0). 
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Figure 4. A.) Untreated RA patients show predominantly interstitial and sheet-like lymphocytic aggregates in response to foreign body 
wear debris. This is significantly different from non-RA patients. Treated RA patients show a mix of perivascular and interstitial 
aggregates in between non-RA and untreated RA patients. In patients with a high prevalence of polyethylene (B) or large particulate 
polyethylene (C), non-RA patients show exclusively a low plasma cell prevalence within lymphocytic aggregates. Untreated RA 
patients show exclusively a high plasma cell prevalence. D.) In patients with a high prevalence of metal particles, untreated RA 
patients show exclusively high plasma cell prevalence within lymphocytic aggregates. ≥ 50% of treated RA patients and non-RA 
patients showed a low plasma cell prevalence. 
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d) Immunohistochemistry 
  A representative convenience sample of peri-prosthetic tissue from 2 non-RA 
cases, 3 treated RA cases, and 3 untreated RA cases was selected for 
immunohistochemical staining. T- and B-lymphocytes were identified by using anti-CD3 
and anti-CD20 antibodies, respectively, and plasma cells by using anti-Kappa and anti-
Lambda antibodies. Repeat evaluation for the presence, type, location, and intensity of 
inflammatory infiltrates using cells identified via immunohistochemistry showed 
identical results to the reviews based on visual identification of cell types. 
 
Radiographic Analysis 
Of the 38 patients in this study, 18 had lateral radiographs and 17 of these 18 had AP 
radiographs available for review. These 18 patients included 5 non-RA, 3 treated RA, 
and 10 untreated RA patients. 
 At the cement-prosthesis interface, none of the RA patients had radiolucencies, 
regardless of treatment. One of five non-RA patients showed radiolucencies. At the 
cement-bone interface, 9 of 18 patients showed radiolucencies, including 2 non-RA, 2 
treated RA and 5 untreated RA patients.  There was no association between the presence 
of radiolucencies and treatment with etanercept, among RA patients (p = 1.0). Similarly, 
there was no difference in the presence of radiolucencies between non-RA and RA 
patients (p = 1.0). 
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Inter/Intra-rater Reliability of Statistical Methods 
 7 of 24 devices and 10 of 38 slides were randomly selected for kappa analysis. 
The inter-rater kappa values were 0.84, 1.0, 0.58, 0.62, 0.29, and 1.0, and the intra-rater 
analysis values were 0.63, 1.0, 0.74, 0.74, 0.55, and 1.0 for location of lymphocytic 
infiltrate, plasma cell prevalence, polyethylene prevalence, polyethylene size, metal 
prevalence, and deformation of the humeral polyethylene bushing respectively. 
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Discussion 
 Our results show that conformational change in the polyethylene bushing is 
strongly associated with large particulate polyethylene debris and a high prevalence of 
metal and polyethylene particles, confirming that conformational change in the bushing is 
due to loss of material, not just deformation. Of note, no difference was found between 
RA and non-RA patients in terms of the severity of device deformation, the composition 
or magnitude of wear debris, or the average pre-operative range of motion, suggesting 
that differences in cellular and tissue reactions cannot be attributed to these factors. The 
only positive association with less conformational change and wear debris was having a 
primary TEA revised <4 years after implantation, regardless of underlying diagnosis. 
 We found an increase in the intensity of lymphocytic aggregates among untreated 
RA patients, which correlated with the presence of metal and polyethylene particles.  
This finding suggests activation of the adaptive immune system in these patients.  
Analysis of the pattern of prosthetic wear revealed that the ulnar and humeral 
polyethylene bushings exhibited extensive wear and fragmentation, including metal 
particle formation related to unintended metal-on-metal wear.  Previous studies reported 
the presence of an inflammatory cell infiltrate and multinucleated giant cells with regions 
of fibrosis as well as focal necrosis associated with extra- and intracellular metallic and 
polymeric particles within histiocytes [25, 41]. Only a minimal lymphocytic reaction was 
found in most cases, and no difference in cellular characteristics was reported between 
patients with or without inflammatory arthritis.  Our study suggests that while no increase 
occurred in the presence of lymphoplasmacytic infiltrates in patients with inflammatory 
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arthritis, the degree of plasma cell infiltrates was significantly increased among those 
with diffuse lymphocytic aggregates. 
 The presence of plasma cells associated with metal wear debris is a characteristic 
histologic feature in patients undergoing revision surgery after metal-on-metal hip 
resurfacing [42, 43].  Diffuse aggregates of lymphocytes and plasma cells are associated 
with regions of tissue necrosis and extensive fibrin deposition.  The reaction is thought to 
represent a hypersensitivity to the metal wear products.  These findings differ 
substantially from those in our series and other TEA series [25, 41], and may represent a 
distinct clinical entity in a weight bearing joint. However, most of the patients on anti-
TNF therapy in our study demonstrated a similar, high prevalence of plasma cells only in 
tissue sites with high metal debris prevalence, suggesting that metal debris may initiate 
the plasmacytic response. The presence of lymphocytic aggregates, however, was 
significantly associated with lower metal particle prevalence. This suggests that while 
metal might specifically bring about a plasmacytic response, polyethylene may be driving 
the broader lymphocytic response in these patients. Though no definitive correlation 
exists between polyethylene and a robust lymphocytic response, prior studies have 
demonstrated lymphocytic infiltrates in response to wear debris even from arthroplasties 
that are not exclusively metal-on-metal [25]. Another possibility is that metal particles in 
the nanometer range, which have been previously described particularly in metal-on-
metal implants and are not counted through visual identification, could cause an 
underestimation of the true metal particle burden and its contribution to a lymphocytic 
response [44]. 
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 Fujishiro et al. recently reviewed a large series of patients undergoing revision 
surgery after total hip replacement for non-metal-on-metal implants [45].  Their series 
was restricted to patients without known inflammatory arthritis, and included patients 
undergoing revision surgery for septic joints.  They noted lymphocytic infiltrates in half 
of the patients with aseptic loosening, 62% of whom demonstrated a diffuse pattern of 
lymphocytic infiltration.  They noted that the diffuse pattern was most commonly 
associated with regions of metal wear accumulation. Only 7% of aseptic cases had 
plasma cells associated with the lymphocytic aggregates.  Their detection of plasma cells 
in a low number of non-RA patients is similar to our findings, and contrasts with the high 
prevalence of these cells in our RA patients. 
 The present study’s findings confirm earlier observations in RA patients 
undergoing revision surgery for failed total knee replacement [38]. Although we detected 
the presence of lymphocytic infiltrates in the tissue from both RA and non-RA patients, 
the pattern of tissue distribution and extent of the infiltrates differed substantially 
between the two patient subsets.  The infiltrates in non-RA patients were focal with 
predominantly perivascular localization and few plasma cells. In contrast, in RA patients 
the infiltrates exhibited both a perivascular and interstitial pattern of distribution and were 
often organized into sheet-like infiltrates with a high proportion of plasma cells. High 
polyethylene particle prevalence and large polyethylene particle size were associated with 
a high plasma cell prevalence within lymphocytic aggregates in RA patients.  In contrast, 
no non-RA patients with many or large polyethylene particles in the peri-implant tissue 
had lymphocytic aggregates with a high plasma cell prevalence.  The prevalence of 
plasma cells in treated RA patients fell between these two groups, suggesting that the 
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reduction in systemic and tissue inflammation associated with anti-TNF therapy results in 
attenuation of the pattern of cellular responses observed in RA patients. 
 Our results provide evidence that patients with RA exhibit a differential cellular 
reaction to inorganic metallic and polyethylene debris compared to patients without RA. 
The tissue reaction in the non-RA patients exhibited features of a non-immune 
granuloma. Lymphocytic infiltrates were scattered within the tissue and limited primarily 
to a perivascular location.  In the untreated RA patients, the presence of more generalized 
lymphocytic infiltrates containing abundant plasma cells are indicative of participation of 
cellular components of both the innate and adaptive immune system, a feature 
characteristic of an “immune granuloma.” These findings recapitulate the observations of 
Caplan and coworkers who described the presence of atypical pulmonary nodules in a 
series of coal miners [46].  Histopathologic analysis of those nodules revealed the 
presence of immune granulomas with extensive lymphocytic infiltration with T and B 
cells. Importantly, these lesions were absent in miners without RA or in RA patients 
without exposure to coal dust, leading to the hypothesis that these findings reflected an 
aberrant immune response to the inorganic components of the coal dust in the RA 
patients.    
 The nature of the underlying immunologic mechanisms by which inorganic 
particles initiate an inflammatory reaction with cellular features of an immune 
granulomatous response remains speculative.  Importantly, this reaction in both peri-
implant tissues and “Caplan’s nodules” develops in the absence of articular cartilage.  
Cartilage matrix components have been implicated as potential immunogens in the 
pathogenesis of RA synovitis; our observations provide evidence that cartilage is not 
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playing a role in the immune response [47].  The association of anti-TNF therapy with 
diminished cellular features of the tissue reaction parallels its known effects in reducing 
inflammatory cell infiltrates in RA synovium [48]. 
 In addition, there was no difference in the presence of radiolucencies between 
patients treated and not treated with etanercept.  While limited by a small sample size and 
the unavailability of three-dimensional imaging, these findings are consistent with other 
studies, which have not found anti-TNF medications to be protective against osteolysis 
[49]. 
 Our data show a trend towards the TEA lasting longer in RA patients compared 
with non-RA patients. This could be due to lower demands placed on the joint 
replacement by RA patients. However, treated RA patients show a length of implantation 
similar to non-RA patients and shorter than untreated RA patients. Users of TNF-
inhibitors may have had better-controlled disease, enabling them to resume normal 
function with higher forces across the joint, accelerating prosthesis loosening. 
 Finally, the inter-rater and intra-rater reliability testing of important qualitative 
variables in our study helps support the integrity of our dataset. The acceptable kappa 
values provide evidence that our scoring methods are reproducible, accurate, and 
unaffected by the personal bias of a scorer directly involved in our study. Having this 
confidence is critical in evaluating the raw data presented in this paper, especially given 
the subjective nature of determining the extent of device wear and recognizing both wear 
debris particles and immunologic cell morphology in peri-prosthetic tissue. However, 
strict, detailed, and previously vetted criteria were used as the basis for all qualitative 
evaluation, and the dependability of the results was confirmed by independent scorers. 
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 In summary, we provide evidence that patients with RA exhibit a differential 
cellular response to prosthetic wear debris compared with non-RA patients, and that this 
reaction is mitigated by the use of anti-TNF inhibitors.  The immune tissue reaction is 
similar to that observed in RA patients exposed to silica, another inorganic particle, and 
specifically consistent with earlier findings of Goldring et. al [38]. Of note, this reaction 
develops in the absence of articular cartilage, which has been implicated in the 
immunopathogenesis of RA synovitis [47, 50]. These results provide evidence of a 
pathogenic activation of the adaptive immune response in RA and could have 
implications for the treatment of peri-implant osteolysis. 
 
Limitations 
 Limitations of our study include the small sample size and retrospective data 
collection. Data were collected cross-sectionally from the time of revision surgery, 
making it impossible to assign causation. Histopathologic analysis was also limited by 
the number of available slides.  Etanercept was FDA approved in 1998.  Patients with 
more severe RA operated on after 1998 may have been more likely to receive a TNF 
inhibitor, a potential systematic bias. However, the fact that anti-TNF therapy was not 
readily available until early 1999 prevented any confounding by indication for the first 
three years of our cohort. Inter-rater and intra-rater reliability testing was performed for 
all key variables in this study except those associated with evaluation of radiographs. The 
previously described scoring system by Goldberg et. al. was specifically designed for a 
TEA and explicit in terms of device evaluation. As a result, only one read of films by an 
expert orthopedic surgeon was performed, but this is a potential limitation of our study. 
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Future Directions 
 Our study helps provide further evidence of an intrinsically altered immune 
response in patients with RA. Validating these results with a larger cohort of patients 
would be an important follow-up study. Increasing the sample size would not only help 
increase the statistical power of the results, but also allow for further stratification of 
patients on the basis of underlying diagnosis, treatment with TNF-inhibitors, or particle 
burden and size without sacrificing on statistical validity. 
 In addition, the immunohistochemistry performed in this study was mainly 
intended to corroborate the findings on light microscopy. As such the cell surface 
markers used were meant to detect T lymphocytes, B lymphocytes, and plasma cells. As 
discussed, however, other subsets of innate and adaptive immune system cells have been 
implicated in RA. These would include activated macrophages, mast cells, Th1 
lymphocytes, and Th17 cells, which can be detected by EMR1-F4/80, CD117, CD26, and 
CD161 cell surface markers respectively[51-54]. Staining for these markers would 
provide a better sense of the absolute numbers of these cells present in the tissue reaction 
of RA patients, which could help further clarify the pathogenesis and natural history of 
RA in the context of wear debris. 
 Furthermore, one of the potential clinical implications of this study is the 
possibility of identifying new pharmacologic targets that could more effectively prevent 
aseptic loosening from peri-prosthetic osteolysis in RA patients. Future studies could 
examine the effectiveness of anti-plasma cell therapy. Such an approach might not only 
reduce the production of anti-CCP antibodies but also reduce the known inflammatory 
reaction induced by metallic wear debris. Medications such as bortezomib, which are 
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used in the context of multiple myeloma, already exist. Moreover, although TNF 
inhibitors appear to somewhat mitigate the inflammatory response seen in RA patients, 
osteolysis is not significantly affected. In order to more directly prevent osteolysis, 
pharmacologic targets could include the RANK/RANK ligand complex, IFN- γ, IL-17, 
or inducible nitric oxide synthase activation.  
 Finally, examining some of the clinical and biomechanical factors that affect the 
speed of implant failure would be another future direction. For instance, establishing the 
prevalence of overuse syndromes in causing device failure would provide anticipatory 
guidance in terms of counseling future arthroplasty patients with or without RA. Future 
studies could also probe changes to the devices themselves to reduce the baseline 
inflammatory response to wear debris. The lymphoplasmacytic response to foreign body 
wear debris suggests that adjusting material choice, density, and manufacturing properties 
could further mitigate the inflammatory response. Altering varus-valgus motion at the 
prosthetic joint or the range of motion, for example, could also be explored in order to 
decrease the speed of implant failure. 
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